On the historical succession of vessel-based therapies in the treatment of multiple sclerosis

9Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Since 2009, the (CCSVI) model of multiple sclerosis has drawn much attention, and the associated surgical 'venoplasty' interventions have often been advertised as a novel idea. In fact, it is a new incarnation of various vessel-based therapies attempted for multiple sclerosis in the past, dating back to the 1930s, when Tracy Jackson Putnam (1894-1975) attempted pharmacological anticoagulation. This was followed in the 1940s by Richard M. Brickner's (1896-1959) studies of vasodilatory drugs, which further inspired trials of sympathectomy and ganglionectomy. In the 1950s, Ilya Mark Scheinker (1902-1954) studied vasopressor therapy, while Roy Laver Swank (1909-2008) investigated the effects of a low saturated fat diet in his patients. This paper discusses the longer history of these therapeutic endeavours and the aetiological theories that inspired them.

Cite

CITATION STYLE

APA

Ganesh, A., & Stahnisch, F. W. (2013). On the historical succession of vessel-based therapies in the treatment of multiple sclerosis. European Neurology, 70(1–2), 48–58. https://doi.org/10.1159/000348780

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free